TheraCode Buys JPT for $6.8M in Bid to Build Biomarker-Discovery Business

TheraCode will use JPT's peptide array resources in its cancer therapeutic discovery programs, though JPT will remain free to offer its products and services to third parties.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories